Research Brief
What Is CJC-1295?
Resposta Rapida
CJC-1295 (DAC:GRF) e um(a) sintetico(a) analogue of hormonio do crescimento-releasing hormone (GHRH) engineered by ConjuChem Biotechnologies (Montréal, Canada) using their proprietary Drug Affinity Complex (DAC) technology. [1] The DAC platform covalently conjugates a reactive maleimide group to o p...
CJC-1295 (DAC:GRF) e um(a) sintetico(a) analogue of hormonio do crescimento-releasing hormone (GHRH) engineered by ConjuChem Biotechnologies (Montréal, Canada) using their proprietary Drug Affinity Complex (DAC) technology. [1] The DAC platform covalently conjugates a reactive maleimide group to o peptideo, que then irreversibly binds the free cysteine residue (Cys-34) of circulating serum albumin — the a maioria abundant plasma protein with a plasma meia-vida of aproximadamente 19 days. [2]
This albumin-piggybacking strategy transforms CJC-1295 from a rapidly cleared peptide (t½ ~30 min for no-DAC analogue) into a long-acting GHRH agonist with an eficaz meia-vida of 6–8 days. No historico Phase I clinical study by Teichman et al. (2006) in adultos saudaveis, a single subcutaneo(a) dose of CJC-1295 produziu sustained, dose-dependente aumenta in GH and IGF-1 concentrations lasting 9–11 days — sem disrupting pulsatile GH secretion patterns. [3]
CJC-1295 tem sido investigado(a) in preclinical and clinical research across varios(as) domains: adult hormonio do crescimento deficiency (GHD), somatopause (age-related GH decline), composicao corporal (lean mass vs. massa gorda), and como um(a) pharmacological model for sustained GH axis estimulacao. It also progressed to Phase II ensaios clinicos in adults with HIV-associated lipodystrophy (fat redistribuicao syndrome), though ConjuChem discontinued development before completion due to company closure. [4]
Diferentemente de direto(a) GH replacement (exogenous rhGH), CJC-1295 estimula the pituitary to produce GH in a physiologically regulou manner — preserving the hypothalamic-pituitary feedback axis and pulsatile secretion profile. Diferentemente de its no-DAC counterpart (Mod GRF 1-29), CJC-1295 with DAC produz continuous tonic GH elevation rather do que discrete pulses, que has distinct physiological implications for IGF-1 synthesis and downstream anabolic signaling. [5]
Referencias
- Jetté L, et al. (2005). Human hormonio do crescimento-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor no(a) anterior pituitary in rats: identification of CJC-1295 como um(a) long-lasting GRF analog. Endocrinology, 146(7):3052–3058.
- Ionescu M, Frohman LA. (2006). Pulsatile secretion of hormonio do crescimento (GH) persists during continuous estimulacao by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab, 91(12):4792–4797.
- Teichman SL, et al. (2006). Prolonged estimulacao of hormonio do crescimento (GH) and insulin-like fator de crescimento I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in adultos saudaveis. J Clin Endocrinol Metab, 91(3):799–805.
- Alba M, et al. (2006). Once-monthly administration of CJC-1295, a long-acting hormonio do crescimento-releasing hormone (GHRH) analog, normalizes growth no(a) GHRH-deficient dwarf rat. Am J Physiol Endocrinol Metab, 291(6):E1290–E1294.
- Walker RF. (2006). Sermorelin: a better approach to management of adult-onset hormonio do crescimento insufficiency? Clin Interv Aging, 1(4):307–308.
- Ben-Shlomo A, et al. (2020). Growth hormone-releasing hormone (GHRH) e seu(sua) analogues: from bench to bedside. Neuroendocrinology, 110(3–4):192–199.
- Gahete MD, et al. (2009). In vivo e em vitro evidence para o(a) importance of hormonio do crescimento-releasing hormone no(a) regulacao of GH secretion. Mol Cell Endocrinol, 309(1–2):40–47.
- FDA. (2024). Substancia Farmaceutica a Granels Under Evaluation for Use in Compounding Under Section 503A: Categoria 2. Docket FDA-2013-N-1525. Federal Register, Dec 2024.
- WADA. (2024). List of Prohibited Substances and Methods. S2: Hormonios Peptidicos, Fatores de Crescimento, Substancias Relacionadas e Mimeticos. World Anti-Doping Agency.
- Frohman LA, Jansson JO. (1986). Growth hormone-releasing hormone. Endocr Rev, 7(3):223–253.
Perguntas de Pesquisa Relacionadas
APENAS PARA USO EM PESQUISA
Este conteudo e fornecido apenas para fins educacionais e informativos. Os produtos sao fornecidos apenas para estudos in vitro e nao sao medicamentos, drogas ou suplementos. Nao aprovado pela FDA para prevenir, tratar ou curar qualquer condicao.